Recombinant human anti-CD20 monoclonal antibody (Sailemin Biotech)

重组人CD20单克隆抗体（赛乐敏生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human anti-CD20 monoclonal antibody (Sailemin Biotech)

Drug Alias Name重组人CD20单克隆抗体注射液（深圳赛乐敏生物）

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (IND)

Highest Status in ChinaDiscontinued

Originator CompaniesSinomab Bioscience (Shenzhen) Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSinomab Bioscience (Shenzhen) Ltd

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A